IMP321: Phase I started

Prima BioMed began the open-label, dose-escalation, Australian Phase I TACTI-mel

Read the full 109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE